Table 1. Effect of the pan-ErbB... | American Society of Hematology

Table 1.

Effect of the pan-ErbB inhibitor on the survival of primary myeloma cells

	Control	Anti-IL-6 MoAb	DEX	ErbB inhibitor	Anti-IL-6 MoAb + ErbB inhibitor	DEX + ErbB inhibitor
Myeloma cell count/mL
Responder patients
Patient 1	30 338	22 880	40 763	26 460	10 075	17 193
Patient 2	78 990	45 090	22 640	61 938	23 088	5 750
Patient 3	30 653	29 952	13 486	17 790	17 460	9 984
Patient 4	14 280	7 560	6 800	6 820	6 528	6 125
Patient 5	162 316	121 856	126 990	42 420	13 900	14 820
Patient 6	68 544	24 795	51 696	2 415	2 080	1 260
Median value	49 599	27 374	31 702	22 125	11 988	8 055
Nonresponder patients
Patient 7	3 824	3 043	3 477	3 040	3 056	3 690
Patient 8	24 922	20 812	24 552	19 560	18 260	16 629
Nonmyeloma cell count/mL
Responder patients
Patient 1	344 663	302 120	334 238	323 540	314 925	307 808
Patient 2	221 010	254 910	257 360	248 062	216 912	244 250
Patient 3	259 347	230 048	206 514	282 210	282 540	230 016
Patient 4	325 720	292 440	293 200	303 180	233 472	243 875
Patient 5	177 684	218 144	213 010	167 580	186 100	185 180
Patient 6	271 456	265 205	188 304	227 585	257 920	198 740
Median value	265 402	260 058	235 185	265 136	245 696	236 946
Nonresponder patients
Patient 7	156 176	166 957	186 523	196 960	156 944	146 310
Patient 8	315 078	199 188	285 448	220 440	201 740	213 371

	Control	Anti-IL-6 MoAb	DEX	ErbB inhibitor	Anti-IL-6 MoAb + ErbB inhibitor	DEX + ErbB inhibitor
Myeloma cell count/mL
Responder patients
Patient 1	30 338	22 880	40 763	26 460	10 075	17 193
Patient 2	78 990	45 090	22 640	61 938	23 088	5 750
Patient 3	30 653	29 952	13 486	17 790	17 460	9 984
Patient 4	14 280	7 560	6 800	6 820	6 528	6 125
Patient 5	162 316	121 856	126 990	42 420	13 900	14 820
Patient 6	68 544	24 795	51 696	2 415	2 080	1 260
Median value	49 599	27 374	31 702	22 125	11 988	8 055
Nonresponder patients
Patient 7	3 824	3 043	3 477	3 040	3 056	3 690
Patient 8	24 922	20 812	24 552	19 560	18 260	16 629
Nonmyeloma cell count/mL
Responder patients
Patient 1	344 663	302 120	334 238	323 540	314 925	307 808
Patient 2	221 010	254 910	257 360	248 062	216 912	244 250
Patient 3	259 347	230 048	206 514	282 210	282 540	230 016
Patient 4	325 720	292 440	293 200	303 180	233 472	243 875
Patient 5	177 684	218 144	213 010	167 580	186 100	185 180
Patient 6	271 456	265 205	188 304	227 585	257 920	198 740
Median value	265 402	260 058	235 185	265 136	245 696	236 946
Nonresponder patients
Patient 7	156 176	166 957	186 523	196 960	156 944	146 310
Patient 8	315 078	199 188	285 448	220 440	201 740	213 371

Mononuclear cells from 8 patients with MM were cultured for 5 days in RPMI 1640 medium, 5% FCS, 1 ng/mL IL-6, with or without the PD169540 ErbB inhibitor (1 μM), B-E8 anti-IL-6 MoAb (10 μg/mL), and DEX (10^-6 M). At day 5 of culture, the viability and cell counts were assayed and the percentage of CD138* viable myeloma cells was determined by flow cytometry. Results are expressed as number of myeloma and nonmyeloma cells per milliliter. The median values were calculated from the 6 responder patients. Two patients did not significantly respond to the 3 compounds, either used alone or in combination

View Large

This Feature Is Available To Subscribers Only